Literature DB >> 22938715

Pulmonary arterial enlargement and acute exacerbations of COPD.

J Michael Wells1, George R Washko, MeiLan K Han, Naseer Abbas, Hrudaya Nath, A James Mamary, Elizabeth Regan, William C Bailey, Fernando J Martinez, Elizabeth Westfall, Terri H Beaty, Douglas Curran-Everett, Jeffrey L Curtis, John E Hokanson, David A Lynch, Barry J Make, James D Crapo, Edwin K Silverman, Russell P Bowler, Mark T Dransfield.   

Abstract

BACKGROUND: Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with accelerated loss of lung function and death. Identification of patients at risk for these events, particularly those requiring hospitalization, is of major importance. Severe pulmonary hypertension is an important complication of advanced COPD and predicts acute exacerbations, though pulmonary vascular abnormalities also occur early in the course of the disease. We hypothesized that a computed tomographic (CT) metric of pulmonary vascular disease (pulmonary artery enlargement, as determined by a ratio of the diameter of the pulmonary artery to the diameter of the aorta [PA:A ratio] of >1) would be associated with severe COPD exacerbations.
METHODS: We conducted a multicenter, observational trial that enrolled current and former smokers with COPD. We determined the association between a PA:A ratio of more than 1 and a history at enrollment of severe exacerbations requiring hospitalization and then examined the usefulness of the ratio as a predictor of these events in a longitudinal follow-up of this cohort, as well as in an external validation cohort. We used logistic-regression and zero-inflated negative binomial regression analyses and adjusted for known risk factors for exacerbation.
RESULTS: Multivariate logistic-regression analysis showed a significant association between a PA:A ratio of more than 1 and a history of severe exacerbations at the time of enrollment in the trial (odds ratio, 4.78; 95% confidence interval [CI], 3.43 to 6.65; P<0.001). A PA:A ratio of more than 1 was also independently associated with an increased risk of future severe exacerbations in both the trial cohort (odds ratio, 3.44; 95% CI, 2.78 to 4.25; P<0.001) and the external validation cohort (odds ratio, 2.80; 95% CI, 2.11 to 3.71; P<0.001). In both cohorts, among all the variables analyzed, a PA:A ratio of more than 1 had the strongest association with severe exacerbations.
CONCLUSIONS: Pulmonary artery enlargement (a PA:A ratio of >1), as detected by CT, was associated with severe exacerbations of COPD. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov numbers, NCT00608764 and NCT00292552.).

Entities:  

Mesh:

Year:  2012        PMID: 22938715      PMCID: PMC3690810          DOI: 10.1056/NEJMoa1203830

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  33 in total

1.  Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers.

Authors:  Sara K Alford; Edwin J R van Beek; Geoffrey McLennan; Eric A Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 2.  Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis.

Authors:  Jacques Rizkallah; S F Paul Man; Don D Sin
Journal:  Chest       Date:  2008-09-23       Impact factor: 9.410

3.  Genetic epidemiology of COPD (COPDGene) study design.

Authors:  Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo
Journal:  COPD       Date:  2010-02       Impact factor: 2.409

4.  Percent emphysema, airflow obstruction, and impaired left ventricular filling.

Authors:  R Graham Barr; David A Bluemke; Firas S Ahmed; J Jeffery Carr; Paul L Enright; Eric A Hoffman; Rui Jiang; Steven M Kawut; Richard A Kronmal; João A C Lima; Eyal Shahar; Lewis J Smith; Karol E Watson
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

5.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Authors:  Leonardo M Fabbri; Peter M A Calverley; José Luis Izquierdo-Alonso; Daniela S Bundschuh; Manja Brose; Fernando J Martinez; Klaus F Rabe
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

6.  Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination.

Authors:  Anand Devaraj; Athol U Wells; Mark G Meister; Tamera J Corte; Stephen J Wort; David M Hansell
Journal:  Radiology       Date:  2010-02       Impact factor: 11.105

7.  Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema.

Authors:  Shin Matsuoka; George R Washko; Tsuneo Yamashiro; Raul San Jose Estepar; Alejandro Diaz; Edwin K Silverman; Eric Hoffman; Henry E Fessler; Gerard J Criner; Nathaniel Marchetti; Steven M Scharf; Fernando J Martinez; John J Reilly; Hiroto Hatabu
Journal:  Am J Respir Crit Care Med       Date:  2009-10-29       Impact factor: 21.405

8.  Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study.

Authors:  Claudio Terzano; Vittoria Conti; Fabio Di Stefano; Angelo Petroianni; Daniela Ceccarelli; Elda Graziani; Salvatore Mariotta; Alberto Ricci; Antonio Vitarelli; Giovanni Puglisi; Corrado De Vito; Paolo Villari; Luigi Allegra
Journal:  Lung       Date:  2010-01-12       Impact factor: 2.584

9.  Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation.

Authors:  Shin Matsuoka; George R Washko; Mark T Dransfield; Tsuneo Yamashiro; Raul San Jose Estepar; Alejandro Diaz; Edwin K Silverman; Samuel Patz; Hiroto Hatabu
Journal:  Acad Radiol       Date:  2009-09-30       Impact factor: 3.173

10.  Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD.

Authors:  C Vassaux; L Torre-Bouscoulet; S Zeineldine; F Cortopassi; H Paz-Díaz; B R Celli; V M Pinto-Plata
Journal:  Eur Respir J       Date:  2008-06-11       Impact factor: 16.671

View more
  180 in total

1.  CT-derived pulmonary vascular metrics and clinical outcome in COVID-19 patients.

Authors:  Pietro Spagnolo; Andrea Cozzi; Riccardo Alessandro Foà; Angelo Spinazzola; Lorenzo Monfardini; Claudio Bnà; Marco Alì; Simone Schiaffino; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2020-06

2.  Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene.

Authors:  Jin Hwa Lee; Michael H Cho; Merry-Lynn N McDonald; Craig P Hersh; Peter J Castaldi; James D Crapo; Emily S Wan; Jennifer G Dy; Yale Chang; Elizabeth A Regan; Megan Hardin; Dawn L DeMeo; Edwin K Silverman
Journal:  Respir Med       Date:  2014-08-11       Impact factor: 3.415

3.  Machine Learning and Prediction of All-Cause Mortality in COPD.

Authors:  Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho
Journal:  Chest       Date:  2020-04-27       Impact factor: 9.410

4.  CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD.

Authors:  Anand S Iyer; J Michael Wells; Sonia Vishin; Surya P Bhatt; Keith M Wille; Mark T Dransfield
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

5.  In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality.

Authors:  Aline N Zouk; J Michael Wells
Journal:  Eur Respir J       Date:  2017-06-15       Impact factor: 16.671

6.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Jeffrey L Curtis; R Graham Barr; Surya P Bhatt; Eugene R Bleecker; Nadia N Hansel; Christopher B Cooper; Mark T Dransfield; J Michael Wells; Eric A Hoffman; Richard E Kanner; Robert Paine; Victor E Ortega; Stephen P Peters; Jerry A Krishnan; Russell P Bowler; David J Couper; Prescott G Woodruff; Fernando J Martinez; Carlos H Martinez; MeiLan K Han
Journal:  Respir Med       Date:  2018-06-05       Impact factor: 3.415

7.  Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh
Journal:  J Allergy Clin Immunol       Date:  2018-04-28       Impact factor: 10.793

8.  Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.

Authors:  Andrew M Courtwright; Bruno G Baldi; Pranav Kidambi; Ye Cui; Anthony M Lamattina; Julian A Villalba; Shefali Bagwe; Hilary J Goldberg; Ivan O Rosas; Elizabeth Petri Henske; Carlos R R Carvalho; Souheil El-Chemaly
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

9.  Independent evaluation of a simple clinical prediction rule to identify right ventricular dysfunction in patients with shortness of breath.

Authors:  Frances M Russell; Christopher L Moore; D Mark Courtney; Christopher Kabrhel; Howard A Smithline; Kristen E Nordenholz; Peter B Richman; Brian J O'Neil; Michael C Plewa; Daren M Beam; Ronald Mastouri; Jeffrey A Kline
Journal:  Am J Emerg Med       Date:  2015-01-22       Impact factor: 2.469

10.  β-Blockers are associated with a reduction in COPD exacerbations.

Authors:  Surya P Bhatt; James M Wells; Gregory L Kinney; George R Washko; Matthew Budoff; Young-Il Kim; William C Bailey; Hrudaya Nath; John E Hokanson; Edwin K Silverman; James Crapo; Mark T Dransfield
Journal:  Thorax       Date:  2015-08-17       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.